BioNexus Gene Lab Corp
BGLC· Nasdaq
BGLCBioNexus Gene Lab Corp
Who holds BioNexus Gene Lab Corp, from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| UBS Group AG | 101 | −56.3% | $197 | 0% | Aug 13, 2026 |
| HRT Financial LP | 14.3K | New | $27 | 0% | Aug 14, 2026 |
| Caitong International Asset Management Co., Ltd | 1 | New | $2 | 0% | Aug 5, 2026 |
